Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$9.93 - $15.39 $195,293 - $302,675
-19,667 Closed
0 $0
Q3 2021

Nov 10, 2021

BUY
$10.18 - $26.64 $88,688 - $232,087
8,712 Added 79.53%
19,667 $201,000
Q2 2021

Aug 11, 2021

SELL
$18.57 - $35.68 $124,159 - $238,556
-6,686 Reduced 37.9%
10,955 $292,000
Q3 2019

Nov 12, 2019

BUY
$36.98 - $48.45 $652,364 - $854,706
17,641 New
17,641 $652,000
Q4 2018

Feb 12, 2019

SELL
$37.97 - $60.16 $2.2 Million - $3.49 Million
-58,018 Closed
0 $0
Q3 2018

Nov 09, 2018

SELL
$56.3 - $67.25 $320,234 - $382,518
-5,688 Reduced 8.93%
58,018 $3.53 Million
Q2 2018

Aug 13, 2018

BUY
$44.9 - $64.95 $2.86 Million - $4.14 Million
63,706 New
63,706 $3.99 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $31.9M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Hap Trading, LLC Portfolio

Follow Hap Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.